DMSO stock comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
While less rhodium than ruthenium and palladium is formed (around 3.6% yield), the mixture of fission products still contains a significant amount of this metal. Due to the high prices of ruthenium, rhodium, and palladium, some work has been done on the separation of these metals to enable them to be used at a later date. Because of the possibility of the metals being contaminated by radioactive isotopes, they are not suitable for making consumer products such as jewellery. However, this source of the metals could be used for catalysts in industrial plants such as petrochemical plants. A dire example of people being exposed to radiation from contaminated jewellery occurred in the United States. It is thought that gold seeds used to contain radon were recycled into jewellery. The gold indeed did contain radioactive decay products of 222Rn. Some other rhodium isotopes exist as "transitory states" of ruthenium, decaying before further decaying towards stable isotopes of palladium. If the low-level radioactivity of palladium (see below) is deemed excessive – for example, for use as an investment or jewellery – either of its predecessors can be extracted from relatively "young" spent fuel and allowed to decay before extracting the stable end-product of the decay series.
== Metabolism in the opium poppy == In Papaver somniferum, there are two possible pathways to morphine from thebaine. These differ according to which methyl group in thebaine is first to be removed in an oxidation reaction.
==== Carnivoran research ==== Evidence of impact of competition on diversification of North American and Eurasian carnivorans throughout the last 45 million years is presented by Porto & Quental (2026). A study on the mandibles of extant and extinct carnivorans, providing evidence of overall decoupling of evolution of mandible shape and function, but also possible evidence of modular dynamics in the evolution of mandible, with differences in the pace and correlation of evolution of different anatomical regions, is published by Sansalone et al. (2026). Bartolini-Lucenti et al. (2026) document new occurrences of carnivorans in the Pliocene strata from the Jradzor locality (Armenia), including Baranogale helbingi, Chasmaporthetes lunensis, Pliocrocuta perrieri and cf. Lynx sp., expanding known geographic and temporal ranges of the studied carnivorans. Orcutt et al. (2026) report the discovery of new carnivoran fossil material from the John Day Formation (Oregon, United States), including the first definitive records of Osbornodon sp. and Otarocyon sp. from the studied formation, as well as a possible fossil material of a large amphicyonine. Espinasa et al. (2026) study the composition of the Rancholabrean carnivoran assemblage from the Calera cave system (San Luis Potosí, Mexico), including a growth sequence of Smilodon fatalis. Díaz de León-Muñoz, Siliceo & Ferreira (2026) study the feeding behavior of Magericyon anceps, reporting evidence of resistance of its mandible to loads during hunting, but also evidence of an unexpectedly weak bite.
Sources: en.wikipedia.org
== Africa == In countries such as Kenya, Lesotho, Mauritius, Nigeria, South Africa, Zambia, and Zimbabwe centenarians are often celebrated upon reaching their 100th Birthday by the locals and government. Former Senegalese President, Abdoulaye Wade, turned 100 on 29 May 2026, becoming the first state leader in West African history to become a centenarian.
In Ancient Greece, the Hippocratic Corpus described the anatomy of the skeleton and muscles. The 2nd century physician Galen of Pergamum compiled classical knowledge of anatomy into a text that was used throughout the Middle Ages. In the Renaissance, Andreas Vesalius (1514–1564) pioneered the modern study of human anatomy by dissection, writing the influential book De humani corporis fabrica. Anatomy advanced further with the invention of the microscope and the study of the cellular structure of tissues and organs. Modern anatomy uses techniques such as magnetic resonance imaging, computed tomography, fluoroscopy and ultrasound imaging to study the body in unprecedented detail.
== Drug interactions == Lamivudine (3TC) significantly inhibits the intracellular phosphorylation of zalcitabine to the active form, and accordingly the drugs should not be administered together. Additionally, zalcitabine should not be used with other drugs that can cause peripheral neuropathy, such as didanosine and stavudine.
Strontium-90 (90Sr) is a radioactive isotope of strontium produced by nuclear fission, with a half-life of 28.91 years. It undergoes β− decay into 90Y (yttrium-90) with a decay energy of 546 keV. 90Sr has applications in medicine and industry and is an isotope of concern in fallout from nuclear weapons, nuclear weapons testing, and nuclear accidents.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.